Side-by-side comparison

ABBV vs ABT — Side-by-side comparison

ABBV screens cheaper on EV/FCF, ABT has the higher ROIC, ABBV has grown revenue faster over five years, and ABT has the cleaner balance sheet by net debt / EBITDA.

ABBV

AbbVie Inc.

Price

$215.70

Market cap

$346.8B

Day %

N/A

ABT

Abbott Labs

Price

$87.41

Market cap

$230.7B

Day %

N/A

Peer Comparison

Target stock against 1 market-cap comparable peer.

Heat map: red worst to green best


ABBV Target	AbbVie Inc.	$346.8B	91.4x	22.8x	6.9%	6.0%	29.1%	N/A	3.7x	N/A
ABT	Abbott Labs	$230.7B	23.5x	31.8x	10.0%	5.1%	16.7%	N/A	0.5x	N/A

ABBV implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

22.8x

FCF yield

5.1%

5Y rev CAGR

6.0%

ABT implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

31.8x

FCF yield

3.2%

5Y rev CAGR

5.1%

5Y indexed stock chart

Static Recharts view indexed to 100 from available annual per-share data.

Quality Scorecard

Build-time composite score for ABBV.

Grade C

/ 100

Quality Scorecard

Build-time composite score for ABT.

Grade C

/ 100